Lilotomab
As of the edition of 20 October 2026, Lilotomab is an antibody: stopped in 2020; acts on CD37.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Antibody
- Registered trials
- 2, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD37 | Leukocyte antigen CD37 | P11049 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Nordic Nanovector | Lead sponsor of trials | 2012 to now |